Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cytokinetics Inc (NASDAQ:CYTK)

9.41
Delayed Data
As of 4:00pm ET
 +0.14 / +1.51%
Today’s Change
5.88
Today|||52-Week Range
13.18
-10.04%
Year-to-Date
Cytokinetics (CYTK) Flagged As Strong On High Volume
Jun 28 / TheStreet.com - Paid Partner Content
Cytokinetics (CYTK) Looks Good: Stock Adds 6.8% in Session
Jun 16 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close9.27
Today’s open9.16
Day’s range9.13 - 9.62
Volume567,492
Average volume (3 months)335,889
Market cap$367.3M
Dividend yield--
Data as of 4:00pm ET, 06/29/2016

Growth & Valuation

Earnings growth (last year)-136.59%
Earnings growth (this year)-54.98%
Earnings growth (next 5 years)+1.00%
Revenue growth (last year)-38.95%
P/E ratioNM
Price/Sales14.17
Price/Book5.35

Competitors

 Today’s
change
Today’s
% change
LJPCLa Jolla Pharmaceuti...+0.21+1.28%
NUTRNutraceutical Intern...+0.01+0.04%
RIGLRigel Pharmaceutical...-0.09-4.00%
LFVNLifeVantage Corp-0.31-2.30%
Data as of 4:00pm ET, 06/29/2016

Financials

Next reporting dateJuly 27, 2016
EPS forecast (this quarter)-$0.31
Annual revenue (last year)$28.7M
Annual profit (last year)-$37.5M
Net profit margin-130.86%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Robert I. Blum
Chief Financial Officer, Secretary &
Executive VP
Sharon A. Barbari
Corporate headquarters
South San Francisco, California

Forecasts

Partner Offers

Search for Jobs